Pramipexole regulates depression-like behavior via dopamine D3 receptor in a mouse model of Parkinson’s disease

Shi-Zhuang Wei,Xiao-Yu Yao,Chen-Tao Wang,An-Qi Dong,Dan Li,Yu-Ting Zhang,Chao Ren,Jin-Bao Zhang,Cheng-Jie Mao,Fen Wang,Chun-Feng Liu
DOI: https://doi.org/10.1016/j.brainresbull.2021.10.015
IF: 3.715
2021-12-01
Brain Research Bulletin
Abstract:Depression is one of the strongest predictors of quality of life in patients with Parkinson's disease (PD). Despite the high prevalence of depression, there is no clear guidance for its treatment in PD because the evidence for the efficacy of most antidepressants remains insufficient. Pramipexole, a dopamine agonist, is one of the few drugs that has proven to be clinically useful. However, the underlying mechanisms of antidepressive effects of pramipexole are still unknown. A 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mouse model, dopamine D2 receptor (DRD2) and D3 receptor (DRD3) knockout mice were used in our study. Compared with other dopamine D2-like receptor agonists and madopar, pramipexole improved depression-like behavior and alleviate bradykinesia in an MPTP-induced mouse model of PD. Pramipexole significantly improved depression-like behavior in DRD2<sup>-/-</sup> mice but not in DRD3<sup>-/-</sup> mice. These results demonstrate that the antidepressive effect of pramipexole is mediated by DRD3 but not DRD2. Our findings highlight the need to develop novel dopamine agonists specifically targeting DRD3 for the treatment of depression in PD in the future.
neurosciences
What problem does this paper attempt to address?